Literature DB >> 17874102

Cholesterol levels in patients with multiple myeloma.

Irfan Yavasoglu1, Murat Tombuloglu, Gurhan Kadikoylu, Ayhan Donmez, Seckin Cagirgan, Zahit Bolaman.   

Abstract

Hypocholesterolemia is seen in solid tumors and some hematological malignancies. We assessed cholesterol levels and the relationship between these levels and types and stages of multiple myeloma (MM) in the patients with MM. One-hundred two patients (60 male and 42 female) of mean age 59 +/- 11 years with MM were enrolled to this study. While 71.6% of the patients were Ig G type, 80.4% of the patients were at stage III. In the control group, there were 71 healthy persons (42 male and 29 female) of mean age 58 +/- 8 years. The levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) in the patients with MM were significantly lower than the controls (p < 0.001). There was no difference for the levels of very-low-density lipoprotein cholesterol and triglyceride between the two groups (p > 0.05). Lipid parameters were not different between Ig types (p > 0.05). The levels of TC and LDL-C in the patients with stage I were higher than those of stages II and III (p < 0.001 and p < 0.005, respectively). The levels of TC and LDL-C in the controls were not higher than the patients with stage I (p > 0.05). HDL-C levels in the patients with stage III were lower than controls (p < 0.001). Hypocholesterolemia are seen in the patients with MM. Hypocholesterolemia may be due to increased LDL clearance and utilization of cholesterol by myeloma cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17874102     DOI: 10.1007/s00277-007-0375-6

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  16 in total

1.  Statin use and risk of multiple myeloma: An analysis from the cancer research network.

Authors:  Mara M Epstein; George Divine; Chun R Chao; Karen E Wells; Heather Spencer Feigelson; Delia Scholes; Douglas Roblin; Marianne Ulcickas Yood; Lawrence S Engel; Andrew Taylor; Joan Fortuny; Laurel A Habel; Christine C Johnson
Journal:  Int J Cancer       Date:  2017-05-15       Impact factor: 7.396

Review 2.  Lipid rafts as signaling hubs in cancer cell survival/death and invasion: implications in tumor progression and therapy: Thematic Review Series: Biology of Lipid Rafts.

Authors:  Faustino Mollinedo; Consuelo Gajate
Journal:  J Lipid Res       Date:  2020-11-07       Impact factor: 5.922

Review 3.  Lipid rafts as signaling hubs in cancer cell survival/death and invasion: implications in tumor progression and therapy.

Authors:  Faustino Mollinedo; Consuelo Gajate
Journal:  J Lipid Res       Date:  2020-01-27       Impact factor: 5.922

4.  The novel anticancer agent JNJ-26854165 induces cell death through inhibition of cholesterol transport and degradation of ABCA1.

Authors:  Richard J Jones; Dongmin Gu; Chad C Bjorklund; Isere Kuiatse; Alan T Remaley; Tarig Bashir; Veronique Vreys; Robert Z Orlowski
Journal:  J Pharmacol Exp Ther       Date:  2013-07-02       Impact factor: 4.030

5.  Metabolic, Anti-apoptotic and Immune Evasion Strategies of Primary Human Myeloma Cells Indicate Adaptations to Hypoxia.

Authors:  Lukas Janker; Rupert L Mayer; Andrea Bileck; Dominique Kreutz; Johanna C Mader; Kirsten Utpatel; Daniel Heudobler; Hermine Agis; Christopher Gerner; Astrid Slany
Journal:  Mol Cell Proteomics       Date:  2019-02-21       Impact factor: 5.911

6.  Serum lipidomics for exploring biomarkers of bortezomib therapy in patients with multiple myeloma.

Authors:  Keiko Maekawa; Masaki Ri; Miki Nakajima; Akihiro Sekine; Ryuzo Ueda; Masahiro Tohkin; Naoki Miyata; Yoshiro Saito; Shinsuke Iida
Journal:  Cancer Sci       Date:  2019-09-19       Impact factor: 6.716

7.  Identification of High Serum Apolipoprotein A1 as a Favorable Prognostic Indicator in Patients with Multiple Myeloma.

Authors:  Lifan Liang; Jing Li; Hangcheng Fu; Xinyang Liu; Peng Liu
Journal:  J Cancer       Date:  2019-08-27       Impact factor: 4.207

8.  Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myeloma.

Authors:  Efrat Markus; Svetlana Trestman; Yael Cohen; Yoel Angel; Yael Sofer; Moshe Mittelman; Irit Avivi; Naftali Stern; Elena Izkhakov
Journal:  BMC Cancer       Date:  2020-05-30       Impact factor: 4.430

Review 9.  Influence of cholesterol on cancer progression and therapy.

Authors:  Shyamananda Singh Mayengbam; Abhijeet Singh; Ajay D Pillai; Manoj Kumar Bhat
Journal:  Transl Oncol       Date:  2021-03-19       Impact factor: 4.243

Review 10.  High Cholesterol Deteriorates Bone Health: New Insights into Molecular Mechanisms.

Authors:  Chandi C Mandal
Journal:  Front Endocrinol (Lausanne)       Date:  2015-10-23       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.